prof. dr hab. Andrzej Pilc

prof. dr hab. Andrzej Pilc

+48 12 6623284
pokój Ojcowska
Zakład Neurobiologii

Dokonania naukowe

  • Publikacje

Effectiveness and safety of vedolizumab for treatment of Crohn's disease: A systematic review and meta-analysis

Autorzy: Mocko, P., Kawalec, P., Smela-Lipinska, B., Pilc, A.

DOI: 10.5114/aoms.2016.61915
Date: 2016-01-01

Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment

Autorzy: Wierońska, J.M., Zorn, S.H., Doller, D., Pilc, A.

DOI: 10.1016/j.pharmthera.2015.10.007
Date: 2016-01-01

Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495

Autorzy: Podkowa, K., Podkowa, A., Sałat, K., Lenda, T., Pilc, A., Pałucha-Poniewiera, A.

DOI: 10.1016/j.neuropharm.2016.08.031
Date: 2016-01-01

Health-related quality of life impairment and indirect cost of Crohn's disease: A self-report study in Poland

Autorzy: Holko, P., Kawalec, P., Mossakowska, M., Pilc, A.

DOI: 10.1371/journal.pone.0168586
Date: 2016-01-01

Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis

Autorzy: Moćko, P., Kawalec, P., Pilc, A.

DOI: 10.1016/j.pharep.2016.07.013
Date: 2016-01-01

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe

Autorzy: Kawalec, P., Sagan, A., Pilc, A.

DOI: 10.1186/s13023-016-0501-4
Date: 2016-01-01

Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland

Autorzy: Stawowczyk, E., Kawalec, P., Pilc, A.

DOI: 10.1002/phar.1742
Date: 2016-01-01

Glutamate-Based Drug Discovery for Novel Antidepressants

Autorzy: Pałucha-Poniewiera, A., Pilc, A.

DOI: 10.1080/17460441.2016.1213234
Date: 2016-01-01

An indirect comparison of in?iximab versus adalimumab or golimumab for active ulcerative colitis

Autorzy: Kawalec, P., Pilc, A.

DOI: 10.5114/aoms.2016.58682
Date: 2016-01-01

Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland

Autorzy: Stawowczyk, E., Kawalec, P., Pilc, A.

DOI: 10.1007/s00228-016-2103-4
Date: 2016-01-01

Zobacz także